Figure S1. (A) Invasive capacities and (B) bar charts of T47D and T47DR cells evaluated using Transwell invasion assays. Magnification, x100, x200 and x400. (C) Western blot analysis and (D) densitometric analysis of E-cadherin and vimentin in T47D and T47DR cells. Data are presented as the means ± standard deviation of the mean of 3 repeats. **P<0.01.

Figure S2. Differential expression of c-MYC was identified in (A) breast cancer tissue (red bar), para-cancer tissue (gray bar) and (B) in different molecular subtypes of breast cancer using data from The Cancer Genome Atlas. *P<0.01. (C) Higher levels of c-MYC were associated with poor distant metastasis free survival of patients with breast cancer. The expression levels of c-MYC predicted post-progress survival in patients with (D) ER$^+$ but not (E) ER$^-$ breast cancer; ER$^+$, estrogen receptor-positive; ER$^-$, estrogen receptor-negative.

Table SI. Sequences of primers used for RT-qPCR analysis.

Gene name	Forward 5'-3'	Reverse 5'-3'
GAPDH	TTCTTTTGCGTCGCCAGCCGA	GTGACCAGGCGCCCAATACGA
c-MYC	AAAGGCCCCCAAGGTAGTTA	GCACAAGAGTTCCGTAGCTG
MRP	ACTTCCTCTATCTCTCCCGACA	AAGACTGAACTCCCTTCCTCCT
MDR	ATTTGACACCCTGGTTGGAG	ACCACTGCTTCGCTTTCTGT
BCPR	CTCAGTTTATCCGTGGTGTGT	GATTGTTCGTCCCTGCTTAGAC

Table SII. The sequences of siRNAs used against c-MYC mRNA.

Gene name		Forward 5'-3'
NC	UUCUCCGAACGUGUCACGUTT	ACGUGACACGUUCGGAGAATT
siRNA-1	GCCACAGCAUACAUCCUGUTT	ACAGGAUGUAUGCUGUGGCTT
siRNA-2	UCCUGAGACAGAUCAGCAATT	UUGCUGAUCUGUCUCAGGATT

Table SIII. Clinical characteristics of primary and recurrent/metastatic specimens in 28 pairs of patients after tamoxifen treatment.

Patient no.	Age (years)	Stage	TTR[a] (months)	Recurrent or metastatic site
1	36	T2N1M0	14	Chest wall
2	48	T2N1M0	14	Lung
3	35	T2N1M0	72	Chest wall
4	45	T2N1M0	48	Chest wall
5	40	T2N2M0	36	Lymph node
6	41	T1N0M0	24	Chest wall
7	26	T2N0M0	24	Chest wall
8	37	T2N1M0	60	Breast
9	34	T3N0M0	84	Lymph node
10	44	T2N2M0	84	Bone
11	29	T2N1M0	48	Cardiac vesicle
12	43	T2N0M0	72	Lymph node
13	46	T3N0M0	48	Lymph node
14	48	T3N2M0	12	Chest wall
15	45	T2N1M0	48	Breast
16	47	T1N1M0	36	Lymph node
17	35	T1N0M0	48	Lymph node
18	42	T2N0M0	36	Breast
19	50	T1N0M0	12	Chest wall
20	52	T3N2M0	7	Chest wall
21	37	T2N0M0	24	Breast
22	37	T2N0M0	30	Lymph node
23	49	T2N1M0	72	Chest wall
24	34	T1N0M0	36	Breast
25	60	T2N2M0	30	Lymph node
26	45	T1N0M0	24	Breast
27	51	T1N1M0	48	Chest wall
28	36	T3N1M0	72	Lymph node

[a]Time to relapse/metastasis: Time since the diagnosis of breast cancer until the diagnosis of metastatic relapse.